Gan & Lee
60308768.731.22% ( +0.83 )
Gan & Lee (603087)
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in...
- Open
- 67.06
- High
- 69.49
- Low
- 66.66
- Prev. Close
- 67.90
- Volume
- 91.98K
- Turnover
- 631.48M
- Avg Price
- 68.65
- Bid/Ask Ratio
- --
- Amplitude
- 4.17%
- 52wk High
- 81.25
- Volume Ratio
- 0.60
- Turnover Ratio
- 1.64%
Gan & Lee Analyst Rating
View MoreForecast & Rating
Jun 10, 2026Price forecast
¥77.0012.03%
Forecast & RatingStrong buy
3analysts
- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- CoinLive · Jul 9 at 04:07 AM
Gan & Lee Pharmaceuticals Wins Honduras Drug Registration for Vitaglar Insulin Glargine Prefilled Pen
- MorningStar · Jun 12 at 07:17 AM
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases — Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
- 同壁财经 · Jun 8 at 09:50 PM
From basic to enhanced, Gan & Lee's GZR4 third item III phase study has met the standards
- 同壁财经 · May 26 at 09:09 AM
Gan & Lee Pharmaceuticals' commercialization layout in the Brazilian market has made further progress, achieving dual compliance from raw materials to formulations
- Pharmaceutical Technology · Apr 10 at 03:42 AM
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
- prnewswire · Mar 31 at 08:37 AM
09:36 ETGan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
